Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tocainide is a small molecule, orally active class 1b antiarrhythmic agent and a primary amine analog of lidocaine. It is used to treat life-threatening ventricular arrhythmias by blocking voltage-gated sodium channels in cardiac cells, particularly in their inactivated state. This action decreases the excitability and automaticity of myocardial cells, stabilizes cardiac membranes, and helps restore normal heart rhythm. Tocainide is structurally related to lidocaine but has better oral bioavailability and a longer half-life. It was marketed under the brand name Tonocard but has been discontinued in some regions[1][2][3][4][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on tocainide.